Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems (Nasdaq: DCTH), an interventional oncology company focusing on liver cancer treatments, has announced its participation in two upcoming investor conferences. The company will attend the BTIG Virtual Biotechnology Conference on August 6, 2024, which will be held virtually. Additionally, Delcath will present at Canaccord Genuity's 44th Annual Growth Conference on August 14, 2024, at 9:30 am Eastern Time in Boston, MA.
These conferences provide Delcath Systems with opportunities to showcase its advancements in liver cancer treatment and engage with investors. The company's participation in both virtual and in-person events demonstrates its commitment to maintaining strong investor relations and promoting its innovative oncology solutions.
Delcath Systems (Nasdaq: DCTH), un'azienda di oncologia interventistica che si concentra sui trattamenti per il cancro al fegato, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda parteciperà alla BTIG Virtual Biotechnology Conference il 6 agosto 2024, che si svolgerà virtualmente. Inoltre, Delcath presenterà alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity il 14 agosto 2024 alle 9:30 ora dell'Est a Boston, MA.
Queste conferenze offrono a Delcath Systems l'opportunità di mettere in mostra i suoi progressi nel trattamento del cancro al fegato e di interagire con gli investitori. La partecipazione dell'azienda a eventi sia virtuali che di persona dimostra il suo impegno a mantenere forti relazioni con gli investitori e a promuovere le sue innovative soluzioni oncologiche.
Delcath Systems (Nasdaq: DCTH), una empresa de oncología intervencionista centrada en tratamientos para el cáncer de hígado, ha anunciado su participación en dos próximas conferencias para inversores. La empresa asistirá a la BTIG Virtual Biotechnology Conference el 6 de agosto de 2024, que se llevará a cabo de forma virtual. Además, Delcath presentará en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity el 14 de agosto de 2024 a las 9:30 a.m., hora del Este, en Boston, MA.
Estas conferencias brindan a Delcath Systems oportunidades para mostrar sus avances en el tratamiento del cáncer de hígado y conectarse con inversores. La participación de la empresa en eventos tanto virtuales como presenciales demuestra su compromiso con el mantenimiento de sólidas relaciones con los inversores y la promoción de sus soluciones oncológicas innovadoras.
Delcath Systems (Nasdaq: DCTH)은 간암 치료에 중점을 둔 중재적 종양학 회사로 두 차례의 투자자 회의에 참가한다고 발표했습니다. 이 회사는 2024년 8월 6일에 온라인으로 열리는 BTIG 가상 생명공학 회의에 참석할 예정입니다. 또한, Delcath는 2024년 8월 14일 오전 9시 30분(미국 동부 시간) 보스턴, MA에서 개최되는 Canaccord Genuity 제44회 연례 성장 회의에서 발표할 것입니다.
이 회의는 Delcath Systems가 간암 치료의 발전을 선보이고 투자자들과 소통할 수 있는 기회를 제공합니다. 회사의 가상 및 대면 이벤트 참여는 투자자 관계를 강화하고 혁신적인 종양학 솔루션을 홍보하려는 의지를 보여줍니다.
Delcath Systems (Nasdaq: DCTH), une entreprise d'oncologie interventionnelle spécialisée dans les traitements du cancer du foie, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise participera à la Conférence Virtuelle de Biotechnologie de BTIG le 6 août 2024, qui se tiendra virtuellement. De plus, Delcath présentera à la 44ème Conférence Annuelle de Croissance de Canaccord Genuity le 14 août 2024 à 9h30, heure de l'Est, à Boston, MA.
Ces conférences offrent à Delcath Systems des opportunités de présenter ses avancées dans le traitement du cancer du foie et de dialoguer avec les investisseurs. La participation de l'entreprise à des événements à la fois virtuels et en personne démontre son engagement à maintenir de solides relations avec les investisseurs et à promouvoir ses solutions oncologiques innovantes.
Delcath Systems (Nasdaq: DCTH), ein Unternehmen für interventionelle Onkologie, das sich auf die Behandlung von Leberkrebs spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird am 6. August 2024 an der BTIG Virtuellen Biotechnologiekonferenz teilnehmen, die virtuell stattfinden wird. Darüber hinaus wird Delcath am 14. August 2024 um 9:30 Uhr Eastern Time in Boston, MA, auf der 44. jährlichen Wachstums-konferenz von Canaccord Genuity präsentieren.
Diese Konferenzen bieten Delcath Systems die Möglichkeit, ihre Fortschritte in der Behandlung von Leberkrebs zu präsentieren und sich mit Investoren auszutauschen. Die Teilnahme des Unternehmens an sowohl virtuellen als auch persönlichen Veranstaltungen zeigt sein Engagement, starke Beziehungen zu Investoren zu pflegen und seine innovativen onkologischen Lösungen zu fördern.
- None.
- None.
BTIG Virtual Biotechnology Conference
Date: Tuesday, August 6, 2024
Location: Virtual
Canaccord Genuity's 44th Annual Growth Conference
Date: Wednesday, August 14, 2024
Presentation Time: 9:30 am Eastern Time
Location:
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.
In
In
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730402570/en/
Investor Relations:
ICR Westwicke
investorrelations@delcath.com
Source: Delcath Systems, Inc.
FAQ
When is Delcath Systems (DCTH) presenting at the Canaccord Genuity Growth Conference?
Which investor conferences will Delcath Systems (DCTH) attend in August 2024?
Is Delcath Systems (DCTH) participating in any virtual conferences?
What is the focus of Delcath Systems (DCTH) as mentioned in the press release?
